Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Mar;8(3-4):E227-34.
doi: 10.5489/cuaj.1015.

National survey addressing the information needs of primary care physicians: Side effect management of patients on androgen deprivation therapy

Tony Soeyonggo  1 , Jennifer Locke  2 , Maria Elizabeth Del Giudice  2 , Shabbir Alibhai  2 , Neil Eric Fleshner  3 , Padraig Warde  4
Affiliations

National survey addressing the information needs of primary care physicians: Side effect management of patients on androgen deprivation therapy

Tony Soeyonggo et al. Can Urol Assoc J. 2014 Mar.

Abstract

Objective: Androgen deprivation therapy (ADT) is a common treatment for prostate cancer with numerous side effects. We assess primary care physicians' (PCPs) knowledge of ADT side effects and their interest in increasing their knowledge in this area.

Methods: A list of active Canadian PCPs was obtained using the Canadian Medical Directory. A cross-sectional survey was distributed to 600 randomly selected physicians. We collected PCPs' demographic information, experience with ADT management, knowledge regarding ADT side effects and desired sources for obtaining knowledge on ADT management.

Results: In total, we received 103 completed questionnaires. Of these, 89% of PCPs had patients on ADT. One-third of respondents prescribed ADT and over half of them administered ADT annually. Thirty-eight percent felt their knowledge of ADT side effects was inadequate and 50% felt uncomfortable counselling patients on ADT. Many PCPs were less familiar with the incidence of functional side effects of ADT (i.e., hot flashes, fatigue and erectile dysfunction) compared to life-threatening side effects (i.e., cardiovascular events, metabolic syndrome, fractures). In terms of increasing their knowledge of ADT side effects, 82% of PCPs would use educational resources if they were available (52% and 32% preferred continued medical education [CME] events and educational pamphlets, respectively).

Conclusions: PCPs play an important role in managing ADT side effects. There is poor awareness of the prevalence of ADT side effects, and many are uncomfortable in managing these side effects. These areas may be addressed through CME programs and educational pamphlets.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Side effects of androgen deprivation therapy.
Fig. 2.
Fig. 2.
Androgen deprivation therapy side effects profile in primary care practitioners’ practice (most frequently reported vs. most medically concerning).
Fig. 3.
Fig. 3.
Educational modalities chosen to be most useful by primary care physicians.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Statistics Canada. 2011 Http://www.cancer.ca. Accessed March 20, 2014.
    1. Allard CB, Dason S, Lusis J, et al. Prostate cancer screening: Attitudes and practices of family physicians in ontario. Can Urol Assoc J. 2012;6:188–93. doi: 10.5489/cuaj.11290. - DOI - PMC - PubMed
    1. Cohen Castel O, Ungar L, Alperin M, et al. Family physicians’ perceptions, beliefs, and attitudes regarding information sharing with prostate cancer patients throughout the course of the disease. Support Care Cancer. 2008;16:955–61. doi: 10.1007/s00520-007-0358-0. - DOI - PubMed
    1. Kim HS, Moreira DM, Smith MR, et al. A natural history of weight change in men with prostate cancer on androgen-deprivation therapy (ADT): Results from the shared equal access regional cancer hospital (SEARCH) database. BJU Int. 2011;107:924–8. doi: 10.1111/j.1464-410X.2010.09679.x. - DOI - PMC - PubMed
    1. Isbarn H, Boccon-Gibod L, Carroll PR, et al. Androgen deprivation therapy for the treatment of prostate cancer: Consider both benefits and risks. Eur Urol. 2009;55:62–75. doi: 10.1016/j.eururo.2008.10.008. - DOI - PMC - PubMed

LinkOut - more resources